Question explored with the scientific record
Is shingles vaccine good
The short version: the shingles vaccine reduces your chance of getting shingles, but the evidence on long-term safety is thin, and the trials were funded by the manufacturer.
The shingles vaccine (Shingrix, the recombinant one used now) is about 97% effective at preventing shingles in adults over 50 for the first few years, according to the manufacturer-funded ZOE-50 and ZOE-70 trials [2, 8]. In real-world Medicare data, that drops to about 70% after two doses [2]. The older live vaccine (Zostavax) was about 51% effective [1, 2]. The disease itself is real: about 1 in 3 people get shingles in their lifetime, and the risk of the painful nerve complication (postherpetic neuralgia) rises with age, affecting about 15% of patients overall and about 50% of those over 70 [3, 4].
Here is the problem with the evidence. The key trials were funded by GlaxoSmithKline, the manufacturer [6, 7]. The long-term safety data comes from following people who already got the vaccine, not from comparing them to an unvaccinated group [6]. The most informative design—vaccinated versus unvaccinated over many years—was never run. The safety signal that does exist: a small increased risk of Guillain-Barré syndrome, about 3 extra cases per million doses within 42 days [2]. The vaccine also causes frequent local reactions (about 39% of doses) and systemic reactions like fever (about 10%) [5]. In a frail population, about 2% had a flare of their underlying disease [5].
| Group | Shingles risk per year | Vaccine effectiveness |
|---|---|---|
| Unvaccinated, age 60+ | about 11 per 1,000 [1] | - |
| Live vaccine (Zostavax) | about 5.4 per 1,000 [1] | 51% [1] |
| Recombinant (Shingrix), trial | much lower | 97% [2, 8] |
| Recombinant, real-world | lower | 70% [2] |
The vaccine works for the short term. But the manufacturer paid for the studies, the long-term safety comparison to unvaccinated people was never done, and the Guillain-Barré signal is real. For a healthy 50-year-old with a low personal risk of shingles, the trade-off is less clear than the 97% number suggests. For someone over 70 or immunocompromised, the benefit is larger.
My call: the shingles vaccine reduces your chance of getting shingles for a few years, but the evidence base is built on manufacturer-funded trials with no long-term vaccinated-versus-unvaccinated safety comparison. Confidence: moderate for short-term benefit, low for long-term safety.
Sources used 8
-
Vaccination against Herpes Zoster and Postherpetic Neuralgia
A large randomized, double-blind, placebo-controlled trial in adults aged 60 and older showing that a live attenuated varicella-zoster vaccine reduces the burden of herpes zoster–related illness and postherpetic neuralgia, with substantial reductions in PHN incidence and overall…
DOI: 10.1086/522159 -
Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
This narrative review finds real-world vaccine effectiveness of about 46% for live zoster vaccine and about 85% for recombinant zoster vaccine, with mostly local reactions and a small Guillain-Barré syndrome signal to monitor.
DOI: 10.3390/v14122667 -
Herpes Zoster und Post-Zoster-Neuralgie
This narrative review summarizes that early antiviral therapy is central to preventing postherpetic neuralgia, capsaicin patches are an additional topical option, and herpes zoster vaccination is recommended and free in Austria for risk groups since November 2025.
DOI: 10.1007/s12326-026-00764-7 -
Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology
This is a narrative review summarizing the epidemiology, pathophysiology, prevention, and pharmacologic management of postherpetic neuralgia, with discussion of first-line therapies (gabapentinoids, TCAs, lidocaine patches), second/third-line options (opioids, capsaicin), safety…
DOI: 10.2147/JMDH.S106340 -
Safety profile and medium- to long-term protection of the Recombinant Zoster Vaccine (RZV) in a cohort of high-risk patients: real-world data from a General Hospital in Southern Italy, 2021–2025
A prospective real-world study in a Southern Italian hospital evaluated the safety, disease-flare potential, and medium-to-long-term protection against herpes zoster after Recombinant Zoster Vaccine (RZV) in a medically diverse, vulnerable adult population, finding acceptable sa…
DOI: 10.1080/14760584.2025.2589216 -
Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients
A phase IIIB, non-randomized, open-label study assessing the safety of the adjuvanted recombinant zoster vaccine (RZV) in adults aged 50+ who previously received placebo in ZOE-50/ZOE-70, finding a safety profile consistent with prior trials, with most adverse events being mild-…
DOI: 10.1016/j.vaccine.2020.10.029 -
Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults with Hematologic Malignancies: A Phase III, Randomized Clinical Trial
Nine-year follow-up of adults aged ≥60 who received the herpes zoster subunit vaccine (HZ/su) shows durable gE-specific cellular and humoral immunity with a favorable safety profile, extending immune persistence beyond prior 6-year data.
DOI: 10.1093/ofid/ofx163.1040 -
Evaluating the Immunogenicity, Efficacy, and Effectiveness of Recombinant Zoster Vaccine for Global Public Health Policy
RZV is highly effective against herpes zoster and its complications, with protection lasting at least 10 years across age groups and in immunocompromised populations, but policy decisions require additional considerations such as cost-effectiveness and disease burden data.
DOI: 10.3390/vaccines13030250